Clinically relevant glioblastoma patient-derived xenograft models to guide drug development and identify molecular signatures

Clinically relevant glioblastoma patient-derived xenograft models to guide drug development and identify molecular signatures

Glioblastoma (GBM) heterogeneity, aggressiveness and infiltrative growth drastically limit success of current standard of care drugs and efficacy of various new therapeutic approaches. There is a need for new therapies and models reflecting the complex biology of these tumors to analyze the molecula...

Full description

Bibliographic Details
Main Authors: Joshua Alcaniz, Lars Winkler, Mathias Dahlmann, Michael Becker, Andrea Orthmann, Johannes Haybaeck, Stefanie Krassnig, Christina Skofler, Tobias Kratzsch, Susanne A. Kuhn, Andreas Jödicke, Michael Linnebacher, Iduna Fichtner, Wolfgang Walther, Jens Hoffmann
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-04-01
Series:Frontiers in Oncology
Subjects:
glioblastoma
glioma
patient-derived xenograft (PDX)
preclinical oncology
drug efficacy
targeted therapy
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1129627/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1129627/full

Similar Items